Skip to main content
Premium Trial:

Request an Annual Quote

Zygogen Provides Curis with Transgenic Zebrafish Technologyx

NEW YORK, Feb 21 – Zygogen of Atlanta, Ga. will provide Curis with its proprietary transgenic zebrafish technology for use in drug discovery, Zygogen said Wednesday.

Zebrafish are similar to knockout mice in that they can serve as model organisms for finding genome-based drug targets, but they offer the advantage of being faster to breed and less expensive.

Zygogen, founded in 1999, uses Z-Tag, a technology through which it can design transgenic zebrafish with organs that are labeled and cell lineages that are delineated. 

"We are pleased to provide Curis with access to Zygogen's zebrafish technology," said Nina Sawczuk, Zygogen’s  CEO. "We are confident that our technology will accelerate their drug screening programs."

This agreement follows closely after the Sanger Center’s announcement it would begin sequencing the full genome of the zebrafish. Other companies, such as Artemis pharmaceuticals of Tubingen, Germany, are also seeking to commercialize zebrafish technology for use in genomic-based drug response studies.  


The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.